EISAI CO LTD (EII MU) stock market data APIs
€26.5298
-0.44(-1.7%)
as of October 27, 2025
Try our APIs with
free plan!
EISAI CO LTD Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.MU.
Prev. Close
26.5298
Open
26.0884
High
26.5298
Low
26.0884
52 wk Range
21.5917-32.5939
Market Cap
15 022 M
EPS
39.18
Dividends (Yield)
1.2903
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD data using free add-ons & libraries
Get EISAI CO LTD Fundamental Data
EISAI CO LTD Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: 32.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD News
New
Health Canada Grants Authorization for Leqembi® (lecanemab)
STOCKHOLM, Oct. 27, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for...
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
Biogen Inc. In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who a...
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alo...
Will Eisai’s (TSE:4523) At-Home Alzheimer’s Injection Redefine Its Competitive Edge in Neuroscience?
Earlier this month, BioArctic AB announced that Leqembi Iqlik, the subcutaneous autoinjector formulation of lecanemab, became available in the U.S. as a maintenance dosing option for early Alzheimer's...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
